Munday, Daniel and Maher, Jane, 1953- (2008) Informed consent and palliative chemotherapy. BMJ, Vol.337 . a868-a868. ISSN 0959-8138

Full text not available from this repository.

Abstract

Better information is needed about prognosis and treatment, along with decision aids to help patients interpret it Informed consent is central to management decisions in modern medical practice. However, sharing information with patients about the value of chemotherapy for advanced metastatic cancer is highly challenging. In the linked study (doi: 10.1136/bmj.a752), Audrey and colleagues assess how much oncologists tell patients about the survival benefit of palliative chemotherapy during the first consultation after a diagnosis of metastatic colorectal cancer, pancreatic cancer, or non-small cell lung cancer.1 Although chemotherapeutic options have improved, life expectancy in people with metastatic cancer is often short, survival benefits of treatment may be modest, and the potential for unpleasant or life threatening side effects is high. Nevertheless, chemotherapy is increasingly given closer to the end of life,2 and patients are having to decide whether or not to have treatment at the same time as facing the harsh realities of dying.

Item Type:	Journal Item
Subjects:	R Medicine > R Medicine (General) R Medicine > RA Public aspects of medicine
Divisions:	Faculty of Medicine > Warwick Medical School > Health Sciences Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH):	Terminal care, Informed consent (Medical law), Cancer -- Palliative treatment, Patient education
Journal or Publication Title:	BMJ
Publisher:	BMJ Group
ISSN:	0959-8138
Date:	31 July 2008
Volume:	Vol.337
Page Range:	a868-a868
Identification Number:	10.1136/bmj.a868
Status:	Peer Reviewed
Publication Status:	Published
URI:	http://wrap.warwick.ac.uk/id/eprint/37278

Request changes to a record

Actions (login required)

View Item